Long-acting HIV jabs to replace daily pills in ‘great step forward’

The NHS has been given the green light to offer people living with HIV the first "long-acting injectable" to keep the virus at bay.

Charities have hailed the "incredible news" which offers an alternative to adults living with HIV who have to take daily antiretroviral drugs.

Many people living with HIV can keep the virus at very low levels by taking antiretroviral tablets each day. These drugs keep the number of virus particles in the blood - also known as the viral load - so low that it cannot be detected or transmitted between people.

But now an estimated 13,000 people will be eligible for the injectable treatment in England which means they no longer need daily treatment but will have two injections every two months. This means they can reduce the days they receive treatment from 365 to 6 per year.

Meindert Boysen, deputy chief executive NICE, said: "Despite scientific advances HIV is still incurable, but the virus can be controlled by modern treatment. However, for some people, having to take daily multi-tablet regimens can be difficult because of drug-related side effects, toxicity, and other psychosocial issues such as stigma or changes in lifestyle."

"We're pleased therefore to be able to recommend cabotegravir with rilpivirine as a valuable treatment option for people who already have good levels of adherence to daily tablets, but who might prefer an injectable regimen with less frequent dosing."

Read full story

Source: 18 November 2021